Sun Pharma voluntarily recalls 11 eye-drop products from India market
Sun Pharmaceutical Industries has withdrawn 11 ophthalmic products from the domestic market as a precautionary quality and patient-safety measure. The company has not disclosed the affected batches, manufacturing sites, cause of the recall or remediation timeline.
What happened
Sun Pharmaceutical Industries · Sun Pharma voluntarily withdrew some ophthalmic products from India’s domestic market, with reports indicating 11 eyedrops. The
Key facts
- 11 eyedrops
- ₹4,721 crore ophthalmology segment
- ₹3,521 crore eyedrops segment
- 12 months up to June 2026
Why this matters
For buyers and partners in ophthalmology, the event reinforces the need to diligence manufacturing controls, recall governance and supply-continuity safeguards in Indian eye-care assets.
What to watch
- Disclosure of affected product names, batches, expiry dates, manufacturing locations and recall cause.
- Any CDSCO or state drug-controller notice, inspection, testing directive or escalation beyond the voluntary recall.
- Evidence of reported adverse events, sterility concerns, particulate contamination or patient-safety alerts.
- Duration of pharmacy stock-outs, distributor return volumes and availability of Sun Pharma replacement inventory.
- Whether the withdrawal expands to more ophthalmic products, export markets or other dosage forms from the same site.
- Comments from hospitals, ophthalmologists, major pharmacy chains or competitors indicating material prescription switching.
- Sun Pharma is likely to issue batch-, product- or channel-specific clarification and provide return, replacement and reimbursement instructions to distributors and pharmacies.
- Pharmacy chains and independent chemists will quarantine listed inventory, reconcile stock with distributors and promote therapeutic substitutes after prescriber or pharmacist consultation.
- Ophthalmologists and hospitals may switch routine prescriptions toward alternative branded or generic formulations until supply status is confirmed.
- Regulators may seek manufacturing, stability, sterility and distribution records and monitor whether similar products require testing or withdrawal.
- Competing eye-care suppliers may increase distributor allocations, field-force activity and inventory placement in affected markets.